{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:03:46Z","timestamp":1740107026731,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,5,14]],"date-time":"2018-05-14T00:00:00Z","timestamp":1526256000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s00432-018-2665-x","type":"journal-article","created":{"date-parts":[[2018,5,14]],"date-time":"2018-05-14T02:53:01Z","timestamp":1526266381000},"page":"1531-1538","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tolerability and efficacy of deferasirox in patients with transfusional iron overload: results from a German 2-year non-interventional study"],"prefix":"10.1007","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2765-8940","authenticated-orcid":false,"given":"Florian","family":"Nolte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"N\u00fcckel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burkhard","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Geer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleg","family":"Rubanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Hebart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Jarisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Johr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Schumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolf-Karsten","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,14]]},"reference":[{"issue":"10","key":"2665_CR1","first-page":"1187","volume":"89","author":"C Borgna-Pignatti","year":"2004","unstructured":"Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC et al (2004) Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 89(10):1187\u20131193","journal-title":"Haematologica"},{"issue":"5","key":"2665_CR2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.leukres.2014.02.003","volume":"38","author":"M Delforge","year":"2014","unstructured":"Delforge M, Selleslag D, Beguin Y, Triffet A, Mineur P, Theunissen K et al (2014) Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes. Leuk Res 38(5):557\u2013563","journal-title":"Leuk Res"},{"issue":"1","key":"2665_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00277-010-1091-1","volume":"90","author":"N Gattermann","year":"2011","unstructured":"Gattermann N, Rachmilewitz EA (2011) Iron overload in MDS-pathophysiology, diagnosis, and complications. Ann Hematol 90(1):1\u201310","journal-title":"Ann Hematol"},{"issue":"9","key":"2665_CR4","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.leukres.2010.03.009","volume":"34","author":"N Gattermann","year":"2010","unstructured":"Gattermann N, Finelli C, Porta MD, Fenaux P, Ganser A, Guerci-Bresler A et al (2010) Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res 34(9):1143\u20131150","journal-title":"Leuk Res"},{"issue":"7","key":"2665_CR5","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1111\/trf.13036","volume":"55","author":"IH Kim","year":"2015","unstructured":"Kim IH, Moon JH, Lim SN, Sohn SK, Kim HG, Lee GW et al (2015) Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload. Transfusion 55(7):1613\u20131620","journal-title":"Transfusion"},{"issue":"21","key":"2665_CR6","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1182\/blood.V118.21.2776.2776","volume":"118","author":"RS Komrokji","year":"2011","unstructured":"Komrokji RS, Ali NHA, Padron E, Lancet JE, List AF (2011) Impact of iron chelation therapy on overall survival and AML transformation in lower risk MDS patients treated at the moffitt cancer center. Blood 118(21):2776","journal-title":"Blood"},{"issue":"6","key":"2665_CR7","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/ejh.12674","volume":"96","author":"R Latagliata","year":"2016","unstructured":"Latagliata R, Montagna C, Porrini R, Di Veroli A, Leonetti SC, Niscola P et al (2016) Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase. Eur J Haematol 96(6):643\u2013649","journal-title":"Eur J Haematol"},{"issue":"14","key":"2665_CR8","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1182\/blood-2010-01-261289","volume":"116","author":"JW Lee","year":"2010","unstructured":"Lee JW, Yoon SS, Shen ZX, Ganser A, Hsu HC, Habr D et al (2010) Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood 116(14):2448\u20132454","journal-title":"Blood"},{"issue":"3","key":"2665_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3816\/CLK.2008.n.026","volume":"2","author":"HALC Leitch","year":"2008","unstructured":"Leitch HALC., Goodman TA et al (2008) Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy. Clin Leuk 2(3):205\u2013211","journal-title":"Clin Leuk"},{"issue":"1","key":"2665_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/bjh.14825","volume":"179","author":"HA Leitch","year":"2017","unstructured":"Leitch HA, Parmar A, Wells RA, Chodirker L, Zhu N, Nevill TJ et al (2017) Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis. Br J Haematol 179(1):83\u201397","journal-title":"Br J Haematol"},{"issue":"17","key":"2665_CR11","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1200\/JCO.2010.34.1222","volume":"30","author":"AF List","year":"2012","unstructured":"List AF, Baer MR, Steensma DP, Raza A, Esposito J, Martinez-Lopez N et al (2012) Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol 30(17):2134\u20132139","journal-title":"J Clin Oncol"},{"issue":"9220","key":"2665_CR12","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(00)02357-6","volume":"355","author":"B Modell","year":"2000","unstructured":"Modell B, Khan M, Darlison M (2000) Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 355(9220):2051\u20132052","journal-title":"Lancet"},{"issue":"8","key":"2665_CR13","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.leukres.2012.04.006","volume":"36","author":"J Neukirchen","year":"2012","unstructured":"Neukirchen J, Fox F, Kundgen A, Nachtkamp K, Strupp C, Haas R et al (2012) Improved survival in MDS patients receiving iron chelation therapy\u2014a matched pair analysis of 188 patients from the Dusseldorf MDS registry. Leuk Res 36(8):1067\u20131070","journal-title":"Leuk Res"},{"issue":"2","key":"2665_CR14","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00277-012-1594-z","volume":"92","author":"F Nolte","year":"2013","unstructured":"Nolte F, Hochsmann B, Giagounidis A, Lubbert M, Platzbecker U, Haase D et al (2013) Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. Ann Hematol 92(2):191\u2013198","journal-title":"Ann Hematol"},{"issue":"7","key":"2665_CR15","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.leukres.2009.12.004","volume":"34","author":"C Rose","year":"2010","unstructured":"Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A et al (2010) Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). Leuk Res 34(7):864\u2013870","journal-title":"Leuk Res"},{"issue":"5","key":"2665_CR16","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/ajh.24668","volume":"92","author":"AT Taher","year":"2017","unstructured":"Taher AT, Origa R, Perrotta S, Kourakli A, Ruffo GB, Kattamis A et al (2017) New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study. Am J Hematol 92(5):420\u2013428","journal-title":"Am J Hematol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-018-2665-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-018-2665-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-018-2665-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T20:18:59Z","timestamp":1571343539000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-018-2665-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,14]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["2665"],"URL":"https:\/\/doi.org\/10.1007\/s00432-018-2665-x","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"type":"print","value":"0171-5216"},{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2018,5,14]]},"assertion":[{"value":"20 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"FN has received research funding and honoraria from Novartis Pharma GmbH; HN, BS, TG, OR, HH, AJ and CS declare no conflict of interest; SA, CJ are employees of Novartis Pharma GmbH; WKH has received research funding from Novartis Pharma GmbH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in the trial involving human participants were in accordance with ethical standards of the national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}